#c. diff. clinical study

[cdifffoundation]

In-Home Enrollment Of Randomized Controlled Trials Finds To Be An Innovative Method Improving Access To Clinical Research

In-Home Enrollment Of Randomized Controlled Trials Finds To Be An Innovative Method Improving Access To Clinical Research

Abstract Introduction: Clostridioides difficile infection is the leading cause of infectious diarrhea in the United States, with substantial morbidity and mortality. Recurrent infection is especially challenging, with each recurrence increasing the likelihood of a successive recurrence, leading to cycles of prolonged symptoms, frequent antimicrobial use, and decreased quality of life. Fecal…

View On WordPress

[cdifffoundation]

Clinical Trial Study Moving Closer to Having Safe and Effective Products to Restore the Gut Microbiome for Patients with Recurrent C. difficile Infections.

Clinical Trial Study Moving Closer to Having Safe and Effective Products to Restore the Gut Microbiome for Patients with Recurrent C. difficile Infections.

Sahil Khanna, M.B.B.S.

A new study published online in the journal ClinicalInfectious Diseases looked at the use of a non-frozen capsule of microbiome restoration therapy for treating patients with recurrent C. difficile infection.

“Patients with C. difficile are typically managed with antibiotics or fecal transplantation for recurrent C. difficile,” says the study’s author, Sahil…

View On WordPress

[cdifffoundation]

Rebiotix and Ferring Pharmaceuticals Announced Positive Preliminary Findings From Their Ongoing Pivotal Phase 3 Trial Of the Investigational Microbiome-based Treatment RBX2660

Rebiotix and Ferring Pharmaceuticals Announced Positive Preliminary Findings From Their Ongoing Pivotal Phase 3 Trial Of the Investigational Microbiome-based Treatment RBX2660

This is a promising approach to managing CDI. Completion of a Phase 3 study, with positive results, is exciting and holds much promise for patients suffering with recurrent C. diff. infections. We look forward to the final results and are truly grateful.

  Rebiotix and Ferring announce world’s first with positive preliminary pivotal Phase 3 data for investigational microbiome-based therapy RBX2660

View On WordPress

[cdifffoundation]

Rebiotix Announces Expansion of Phase 1 Study For Prevention of Recurrent C.diff. Infection Oral Capsule Microbiota Product RBX7455

Rebiotix Announces Expansion of Phase 1 Trial of the Company’s Oral Capsule Microbiota Product, RBX7455, Following Successful Completion of Initial Study Arms Additional cohorts to examine potential of reduced dosing regimens of RBX7455 for the prevention of recurrent Clostridium difficile infection Rebiotix Inc., a clinical-stage microbiome company focused on harnessing the power of the human…

View On WordPress

[cdifffoundation]

Inquire and Consider Becoming A Candidate In a C. difficile Infection Clinical Trial To Help You - Help Them - Help Others

Inquire and Consider Becoming A Candidate In a C. difficile Infection Clinical Trial To Help You – Help Them – Help Others

Every scientific research and development, every clinical trial in progress is a glimmer of hope………..HOPE for clinically safe and approved avenues to prevent and treat a C. difficile infection.

    Listed below you will find a web link that will redirect you to obtain information that pertains to organizations who have on-going C. difficile Prevention and Treatment clinical trials in progress.  

C…

View On WordPress

[cdifffoundation]

Seres Therapeutics Share Key Findings From Earlier Reported SER-109 Phase 2 Clinical Study Outcome

Seres Therapeutics Share Key Findings From Earlier Reported SER-109 Phase 2 Clinical Study Outcome

As published in Seres Therapeutics Press Release  January 31, 2017

  Findings suggest that both misdiagnosis of C. difficile recurrent infection in some patients, and dosing that may have been suboptimal in certain patients, contributed to the previously reported SER-109 Phase 2 study outcome –

FDA discussions are ongoing regarding a new, redesigned clinical study for SER-109

CAMBRIDGE, Mass.,…

View On WordPress

[cdifffoundation]

July 12th Join C. diff. Spores and More With Dr. Garey and Dr. Vickers As We Discuss Summit Therapeutics: Ridinilazole, a Microbiome Preserving Antibiotic For the Treatment Of C. difficile Infection (CDI)

July 12th Join C. diff. Spores and More With Dr. Garey and Dr. Vickers As We Discuss Summit Therapeutics: Ridinilazole, a Microbiome Preserving Antibiotic For the Treatment Of C. difficile Infection (CDI)

  Listen to the live broadcast aired on July 5th,  2016

CLICK ON THE LOGO TO BE REDIRECTED TO LISTEN TO THE BROADCAST

Listen in to the live broadcast at 10a PT,   11a MT,   12p CT,   1p ET     6p UK

“C. diff. Spores and More,”™ Global Broadcasting Network – innovative and educational interactive healthcare talk radio program discusses

This Episode:  

Summit Therapeutics: ridinilazole, a…

View On WordPress

[cdifffoundation]

July 5th Join C. diff. Spores and More With Dr. Garey and Dr. Vickers As We Discuss Summit Therapeutics: Ridinilazole, a Microbiome Preserving Antibiotic For the Treatment Of C. difficile Infection (CDI)

July 5th Join C. diff. Spores and More With Dr. Garey and Dr. Vickers As We Discuss Summit Therapeutics: Ridinilazole, a Microbiome Preserving Antibiotic For the Treatment Of C. difficile Infection (CDI)

  Listen to the live broadcast on  July 5th,  2016

CLICK ON THE LOGO TO BE REDIRECTED TO THE  LIVE BROADCAST PAGE

Listen in to the live broadcast at 10a PT,   11a MT,   12p CT,   1p ET     4p UK

“C. diff. Spores and More,”™ Global Broadcasting Network – innovative and educational interactive healthcare talk radio program discusses

This Episode:  

Summit Therapeutics: ridinilazole, a microbiome…

View On WordPress